RWR,
In 96 when I become SI member and started NXTR tread I make clear how I value any bt/pharma:
1. How they develop new drug,
2. How they manufacture (or secure from contract) drug,
3. How they market and sell drug
Small bt can chose only first step and virtually integrate 2. and 3. part. However, by this they are missing big chunk of the profit.
REGN approach is to integrate all three part in business model. So, ability to execute second part is significant step forward and did add value. Will WS or street recognize this or not, bit's me? This value may not be recognized today or tomorrow, but when BDNF reach NDA application status investors will look back. So, as long as my model work and I am satisfied with it I can be relaxed and continue to follow drug development progress.
Focus on REGN drug pipeline should be main objective here. I agree.
What is your opinion on BDNF, NT3, Axokine, cytokine traps, MAP kinases, angiogenesis, ....?
Looking forward for few beers.
Miljenko
|
